Targeted temperature management in patients with intracerebral haemorrhage, subarachnoid haemorrhage, or acute ischaemic stroke: updated consensus guideline recommendations by the Neuroprotective Therapy Consensus Review (NTCR) group.

guidelines intensive care intracerebral haemorrhage neurocritical care normothermia stroke subarachnoid haemorhhage targeted temperature management

Journal

British journal of anaesthesia
ISSN: 1471-6771
Titre abrégé: Br J Anaesth
Pays: England
ID NLM: 0372541

Informations de publication

Date de publication:
08 2023
Historique:
received: 23 01 2023
revised: 03 04 2023
accepted: 17 04 2023
medline: 24 7 2023
pubmed: 25 5 2023
entrez: 24 5 2023
Statut: ppublish

Résumé

There is a lack of consistent, evidence-based guidelines for the management of patients with fever after brain injury. The aim was to update previously published consensus recommendations on targeted temperature management after intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke in patients who require admission to critical care. A modified Delphi consensus, the Neuroprotective Therapy Consensus Review (NTCR), included 19 international neuro-intensive care experts with a subspecialty interest in the acute management of intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke. An online, anonymised survey was completed ahead of the meeting before the group came together to consolidate consensus and finalise recommendations on targeted temperature management. A threshold of ≥80% for consensus was set for all statements. Recommendations were formulated based on existing evidence, literature review, and consensus. After intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke in patients who require critical care admission, core temperature should ideally be monitored continuously and maintained between 36.0°C and 37.5°C using automated feedback-controlled devices, where possible. Targeted temperature management should be commenced within 1 h of first fever identification with appropriate diagnosis and treatment of infection, maintained for as long as the brain remains at risk of secondary injury, and rewarming should be controlled. Shivering should be monitored and managed to limit risk of secondary injury. Following a single protocol for targeted temperature management across intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke is desirable. Based on a modified Delphi expert consensus process, these guidelines aim to improve the quality of targeted temperature management for patients after intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke in critical care, highlighting the need for further research to improve clinical guidelines in this setting.

Sections du résumé

BACKGROUND
There is a lack of consistent, evidence-based guidelines for the management of patients with fever after brain injury. The aim was to update previously published consensus recommendations on targeted temperature management after intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke in patients who require admission to critical care.
METHODS
A modified Delphi consensus, the Neuroprotective Therapy Consensus Review (NTCR), included 19 international neuro-intensive care experts with a subspecialty interest in the acute management of intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke. An online, anonymised survey was completed ahead of the meeting before the group came together to consolidate consensus and finalise recommendations on targeted temperature management. A threshold of ≥80% for consensus was set for all statements.
RESULTS
Recommendations were formulated based on existing evidence, literature review, and consensus. After intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke in patients who require critical care admission, core temperature should ideally be monitored continuously and maintained between 36.0°C and 37.5°C using automated feedback-controlled devices, where possible. Targeted temperature management should be commenced within 1 h of first fever identification with appropriate diagnosis and treatment of infection, maintained for as long as the brain remains at risk of secondary injury, and rewarming should be controlled. Shivering should be monitored and managed to limit risk of secondary injury. Following a single protocol for targeted temperature management across intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke is desirable.
CONCLUSIONS
Based on a modified Delphi expert consensus process, these guidelines aim to improve the quality of targeted temperature management for patients after intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, and acute ischaemic stroke in critical care, highlighting the need for further research to improve clinical guidelines in this setting.

Identifiants

pubmed: 37225535
pii: S0007-0912(23)00205-2
doi: 10.1016/j.bja.2023.04.030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

294-301

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Andrea Lavinio (A)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Electronic address: andrea.lavinio1@nhs.net.

John Andrzejowski (J)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Ileana Antonopoulou (I)

Nottingham University Hospitals NHS Trust, Nottingham, UK.

Jonathan Coles (J)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; University of Cambridge, Cambridge, UK.

Pierce Geoghegan (P)

Beaumont Hospital, Dublin, Ireland.

Kyle Gibson (K)

National Hospital for Neurology and Neurosurgery, London, UK.

Sandeep Gudibande (S)

Lancashire Teaching Hospitals NHS Trust, Preston, UK.

Carmen Lopez-Soto (C)

King's College Hospital NHS Foundation Trust, London, UK.

Randeep Mullhi (R)

University Hospitals Birmingham NHS Trust, Birmingham, UK.

Priya Nair (P)

The Walton Centre NHS Foundation Trust, Liverpool, UK.

Vijai P Pauliah (VP)

The Walton Centre NHS Foundation Trust, Liverpool, UK.

Aoife Quinn (A)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Frank Rasulo (F)

Spedali Civili University Hospital of Brescia, Brescia, Italy.

Andrew Ratcliffe (A)

Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Ugan Reddy (U)

National Hospital for Neurology and Neurosurgery, London, UK.

Jonathan Rhodes (J)

NHS Lothian Hospitals, Edinburgh, UK.

Chiara Robba (C)

Ospedale Policlinicio San Martino, Genova, Italy.

Matthew Wiles (M)

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Ashleigh Williams (A)

University Hospitals Plymouth NHS Trust, Plymouth, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH